ARCHIVES

Phase III Xtandi Trial Meets Primary Endpoints Of Progression-Free and Overall Survival

This article is from The Cancer Letter archive.

Vol. 36 No. 11 | November 29, 2013

Download PDF Visit The Full Archive

Related Articles

ACS Creates $1 Billion Nationwide Organization, Taking Fiduciary Control From 12 Divisions

November 18, 2011

“Clinical research of all kinds in the IRP lacks a rigorous, centralized process for peer review.”

July 21, 1995

Bayer’s HER-2/neu Blood Test Cleared By FDA For Marketing.

December 15, 2000

Symposium to Focus on New Approaches to Drug Resistance

May 11, 1990

Lung Cancer Size May Not Indicate Severity Of Disease

March 29, 2002

Monica Bertagnolli Elected Chair Of The Alliance For Clinical Trials In Oncology

July 15, 2011